Mankind Pharma
ListedPharmaceuticals2023One of India's largest domestic-focused pharma companies, known for mass-market brands. A steady post-listing compounder.
Company Overview
Mankind Pharma develops, manufactures and markets pharmaceutical formulations and consumer healthcare products, with a strong presence in the domestic chronic and acute therapy markets.
Primarily domestic prescription and OTC sales through an extensive field force, with affordable mass-market brands driving volume-led growth.
The Indian pharma market is structurally growing on rising incomes, insurance penetration and chronic-disease prevalence.
IPO Details
Market Performance
Financials
Revenue CAGR +15.3%| Fiscal Year | Revenue | Profit | EBITDA | Net Worth | Debt |
|---|---|---|---|---|---|
| FY22 | ₹7,782 Cr | ₹1,453 Cr | ₹1,900 Cr | ₹6,100 Cr | ₹80 Cr |
| FY23 | ₹8,749 Cr | ₹1,310 Cr | ₹1,850 Cr | ₹7,400 Cr | ₹60 Cr |
| FY24 | ₹10,335 Cr | ₹1,941 Cr | ₹2,550 Cr | ₹9,300 Cr | ₹1,500 Cr |
All figures in ₹ crore.
Price History
IPO Price vs Current
Returns
Key Numbers
News & Updates
- 22 May 2025
Mankind reports double-digit revenue growth in FY25
Business Standard
- 25 Jul 2024
Completes acquisition to enter premium chronic segment
Economic Times
SWOT Analysis
- • Strong domestic brand portfolio
- • Wide distribution reach
- • Healthy margins and low debt historically
- • Limited export diversification
- • Acquisition-led debt increase
- • Premiumisation in chronic therapies
- • Consumer healthcare expansion
- • Price controls (NLEM)
- • Intense generic competition
Figures are illustrative sample data for demonstration — not investment advice.